Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
InnerScope Hearing Technologies, Inc. (INND)
Roseville, CA, US
InnerScope Hearing Technologies, Inc. specializes in delivering a variety of hearing solutions, primarily supplying the retail hearing aid community with its array of hearing aids and personal sound amplification devices, available in both hearable and wearable forms. The company's operations encompass the manufacturing and direct-to-consumer distribution and sales of these devices. Beyond hardware, InnerScope also offers a suite of related products and services, which include hearing-related therapeutic treatments, physician-developed dietary supplements aimed at supporting hearing health, and a unique CBD oil specifically formulated for managing tinnitus. Expanding its comprehensive approach, InnerScope manages and operates eleven audiological and retail hearing device clinics. Additionally, it provides a business-to-business (B2B) software-as-a-service (SaaS) platform for patient management. Founded in 2012 as Innerscope Advertising Agency, Inc., the company officially adopted its current name, InnerScope Hearing Technologies, Inc., in August 2017, and its corporate headquarters are located in Roseville, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -33.33% | -60.00% | -80.00% | -84.62% | -80.00% | -96.00% | -99.99% | -100.00% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Instruments & Supplies: +7.9%-72.8% Q4'25: +118.4% (vs Q4'24)
-
EPS growth Medical - Instruments & Supplies: +16.3%-100.3% Q4'25: -99.4% (vs Q4'24)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-557.8% Q4'25: -481.5% (vs Q4'24)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-499.6% Q4'25: +75.0% (vs Q4'24)
-
ROIC Medical - Instruments & Supplies: +6.0%-0.8% Q4'25: +0.2% (vs Q4'24)
-
Share dilution Medical - Instruments & Supplies: +0.1%+1,015.1% Q4'25: +1,015.1% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×-10.20× Q4'25: 39.21× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IDENTIFICATION NOS. OF ABOVE PERSONS ( | 1.30B | 9.57% | 1.30B | — | 1.30B | — | IN | Virginia | 2024-03-04 | ↗ |
| 2 | Swedbank Robur Fonder AB | 2.04M | 7.80% | 9.04M | — | 9.04M | — | FI | United States of America, State of Minnesota | 2018-11-09 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-03-17 | Moore Matthew Ross | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 2,500 | 0.30 | 750.00 | 445,000 | — | ↗ |
| 2017-03-15 | Moore Matthew Ross | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 2,500 | 0.25 | 625.00 | 447,500 | — | ↗ |
| 2017-02-22 | Moore Matthew Ross | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 450,000 | — | ↗ |
| 2017-02-22 | Moore Mark Lee | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 19,020,000 | — | ↗ |
| 2017-02-22 | Moore Kimberly Ann | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 19,020,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Matthew Ross Moore | Founder, Chief Executive Officer, President, Secretary & Director | 225.0K | male |
| Kimberly A. Moore | Chief Financial Officer, Treasurer & Director | 150.0K | female |
| Doug Qualset | Vice President of Finance & Chief Accountant | — | male |
| Adnan Shennib | Chief Technology Officer | — | male |
| Mark Lee Moore | Founder & Chairman | — | male |
| Chris Ivery | Chief Brand Advisor | — | male |
| Seth Greene | Chief Marketing Officer | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INND
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
